304 related articles for article (PubMed ID: 34344291)
1. Current and Emerging Treatments for Methamphetamine Use Disorder.
Moszczynska A
Curr Neuropharmacol; 2021; 19(12):2077-2091. PubMed ID: 34344291
[TBL] [Abstract][Full Text] [Related]
2. Treatments for methamphetamine abuse: a literature review for the clinician.
Brackins T; Brahm NC; Kissack JC
J Pharm Pract; 2011 Dec; 24(6):541-50. PubMed ID: 22095579
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatments for methamphetamine addiction: current status and future directions.
Ballester J; Valentine G; Sofuoglu M
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):305-314. PubMed ID: 27927042
[TBL] [Abstract][Full Text] [Related]
4. Oxytocin-enhanced motivational interviewing group therapy for methamphetamine use disorder in men who have sex with men: study protocol for a randomized controlled trial.
Stauffer CS; Moschetto JM; McKernan SM; Hsiang E; Borsari B; Woolley JD
Trials; 2019 Feb; 20(1):145. PubMed ID: 30791944
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups.
Soares E; Pereira FC
Expert Opin Pharmacother; 2019 Dec; 20(18):2273-2293. PubMed ID: 31671001
[No Abstract] [Full Text] [Related]
6. Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors.
Keller CM; Spence AL; Stevens MW; Owens SM; Guerin GF; Goeders NE
Psychopharmacology (Berl); 2020 Mar; 237(3):655-667. PubMed ID: 31758209
[TBL] [Abstract][Full Text] [Related]
7. Modeling methamphetamine use disorder in mammals: Sex differences in behavioral, biochemical, and transcriptional consequences.
Daiwile AP; Cadet JL
Adv Pharmacol; 2024; 99():145-168. PubMed ID: 38467480
[TBL] [Abstract][Full Text] [Related]
8. The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse.
Hay CE; Ewing LE; Hambuchen MD; Zintner SM; Small JC; Bolden CT; Fantegrossi WE; Margaritis P; Owens SM; Peterson EC
J Pharmacol Exp Ther; 2020 Jul; 374(1):16-23. PubMed ID: 32245884
[TBL] [Abstract][Full Text] [Related]
9. The neurobiological mechanisms of physical exercise in methamphetamine addiction.
Morais APD; Pita IR; Fontes-Ribeiro CA; Pereira FC
CNS Neurosci Ther; 2018 Feb; 24(2):85-97. PubMed ID: 29266758
[TBL] [Abstract][Full Text] [Related]
10. Childhood trauma and METH abuse among men who have sex with men: Implications for intervention.
Lopez-Patton M; Kumar M; Jones D; Fonseca M; Kumar AM; Nemeroff CB
J Psychiatr Res; 2016 Jan; 72():1-5. PubMed ID: 26519763
[TBL] [Abstract][Full Text] [Related]
11. Are Histamine H
Kitanaka N; Hall FS; Tanaka KI; Tomita K; Igarashi K; Nishiyama N; Sato T; Uhl GR; Kitanaka J
Curr Drug Res Rev; 2022; 14(3):162-170. PubMed ID: 35431009
[TBL] [Abstract][Full Text] [Related]
12. Oxytocin-enhanced group therapy for methamphetamine use disorder: Randomized controlled trial.
Stauffer CS; Moschetto JM; McKernan S; Meinzer N; Chiang C; Rapier R; Hsiang E; Norona J; Borsari B; Woolley JD
J Subst Abuse Treat; 2020 Sep; 116():108059. PubMed ID: 32741502
[TBL] [Abstract][Full Text] [Related]
13. Oxytocin treatment in the prelimbic cortex reduces relapse to methamphetamine-seeking and is associated with reduced activity in the rostral nucleus accumbens core.
Everett N; Baracz S; Cornish J
Pharmacol Biochem Behav; 2019 Aug; 183():64-71. PubMed ID: 31202809
[TBL] [Abstract][Full Text] [Related]
14. Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence.
Chen H; Wu J; Zhang J; Hashimoto K
Curr Drug Abuse Rev; 2010 Dec; 3(4):222-38. PubMed ID: 21208168
[TBL] [Abstract][Full Text] [Related]
15. The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats.
Pittenger ST; Barrett ST; Chou S; Bevins RA
Behav Brain Res; 2017 Mar; 320():195-199. PubMed ID: 27939341
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Regulatory Dynamics in Models of Methamphetamine-Use Disorder.
Jayanthi S; McCoy MT; Cadet JL
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34681009
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder.
Aryan N; Banafshe HR; Farnia V; Shakeri J; Alikhani M; Rahimi H; Sehat M; Mamsharifi P; Ghaderi A; Omidi A
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):72. PubMed ID: 32977820
[TBL] [Abstract][Full Text] [Related]
18. Transcranial magnetic stimulation for methamphetamine use disorder: A scoping review within the neurocircuitry model of addiction.
Ballester J; Marchand WR; Philip NS
Psychiatry Res; 2024 Aug; 338():115995. PubMed ID: 38852478
[TBL] [Abstract][Full Text] [Related]
19. Methamphetamine-associated cardiomyopathy: an addiction medicine perspective.
Somma V; Osekowski M; Paratz E; Bonomo Y
Intern Med J; 2023 Jan; 53(1):21-26. PubMed ID: 36693638
[TBL] [Abstract][Full Text] [Related]
20. Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults.
Han B; Compton WM; Jones CM; Einstein EB; Volkow ND
JAMA Psychiatry; 2021 Dec; 78(12):1329-1342. PubMed ID: 34550301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
